Asset Transaction (Form 8-K)

As previously disclosed in a Current Report on Form 8-Kfiled by TransMedics Group, Inc. (the "Company") on September 5, 2023, a Current Report on Form 8-Kfiled by the Company on September 12, 2023, a Current Report on Form 8-Kfiled by the Company on September 22, 2023, a Current Report on Form 8-Kfiled by the Company on November 13, 2023, a Current Report on Form 8-Kfiled by the Company on December 19, 2023, a Current Report on Form 8-Kfiled by the Company on January 2, 2024, a Current Report on Form 8-Kfiled by the Company on January 29, 2024, a Current Report on Form 8-Kfiled by the Company on February 6, 2024, a Current Report on Form 8-Kfiled by the Company on March 12, 2024, a Current Report on Form 8-Kfiled by the Company on July 2, 2024, a Current Report on Form 8-Kfiled by the Company on July 29, 2024, a Current Report on Form 8-Kfiled by the Company on September 11, 2024, a Current Report on Form 8-Kfiled by the Company on December 9, 2024, a Current Report on Form 8-Kfiled by the Company on January 14, 2025, and a Current Report on Form 8-Kfiled by the Company on February 21, 2025 (together, the "Prior Reports"), TransMedics, Inc. (the "Buyer"), a Delaware corporation and wholly-owned subsidiary of the Company, acquired 21 fixed-wing aircraft (collectively, the "Prior Acquisitions") as more specifically described in the Prior Reports.

Subsequently, on October 3, 2025, the Buyer acquired a fixed-wing aircraft from Teaghlach Aviation, LLC for a purchase price of approximately $14.5 million (together with the Prior Acquisitions, the "Acquisitions"). The Company intends to use each of the 22 aircraft it has acquired to date to transport donor organs as part of the services offered under the Company's National OCS Program, and for purposes of this Current Report on Form 8-Kthe Company considers the Acquisitions to be a series of related transactions with respect to the acquisition of a fleet of aircraft for use in the Company's National OCS Program.